60 Degrees Pharmaceuticals (NASDAQ: SXTP), signed clinical trial agreements with Yale University, Rhode Island Hospital, and Tufts Medical Center for its groundbreaking Tafenoquine for Babesiosis study. The trial, which has already begun patient enrollment, aims to treat the emerging, tick-borne illness that has seen rising cases in the Northeast U.S. This randomized, double-blind, placebo-controlled study will recruit 24 to 33 patients and expects interim results by September 2025. The potential market for ARAKODA (tafenoquine) for babesiosis in the U.S. is approximately 400,000 patients through the end of patent protection in 2035.
Disclosure
Sixty Degrees is a client of RedChip Companies, Inc. Sixty Degrees agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in March 2023, and $40,000 of Rule 144 stock (based on the 30-day average price after the IPO) for six months of investor awareness services.